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	 In	rummage	around	for	a	novel	antimicrobial	and	antioxidant	agent	with	improved	potency,we	designed	and	synthesized	a	series	of	5H‐dibenz[b,f]azepine	based	pyrazole	sulphonamides
(20‐40)	by	expedient	five	steps	route.	All	compounds	were	characterized	by	physico‐chemical
and	spectroscopic	techniques.	 In	order	to	probe	 the	antimicrobial	and	antioxidant	activities,
the	 newly	 synthesized	 compounds	 were	 assayed	 for	 their	 in	 vitro	 activities.	 Among	 the
compounds	 of	 the	 particular	 interest,	 compounds	 38	 and	 39	 emerged	 as	 outperformed
antimicrobial	agents	than	standard	streptomycin	and	fluconazole.	Molecular	docking	studies
of	compound	38	and	39	into	S.	aureus	tyrosyl‐tRNA	synthetase	active	site	was	performed,	and
the	 tight	 fitting	 of	 the	 compounds	 in	 the	 active	 site	 and	 the	 associated	high	binding	 energy
might	 be	 the	 reason	 for	 their	 antimicrobial	 activity.	 On	 the	 other	 hand,	 compounds	 28‐30
were	 found	 to	 exert	 positive	 efficacy	 towards	 antioxidant	 activity	 comparable	 to	 butylated
hydroxy	anisole.	
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1.	Introduction	
	
The	 biological	 activity	 manifested	 by	 tricyclic,	 nitrogen‐
containing	 heterocyclic	 compounds,	 makes	 them	 attractive	
targets	for	synthetic	chemists	[1‐3].	The	seven‐membered	ring	
5H‐dibenz[b,f]azepine	 nucleus	 (1)	 is	 a	 pharmaceutically	
important	structure	and	constitutes	the	key	subunit	in	tricyclic	
antidepressant	 drug	 substances	 such	 as	 carbamazepine	 (1a)	
and	 oxcarbazepine	 (1b)	 (Figure	 1)	 [4].	 These	 anticonvulsant	
and	 mood	 stabilizing	 drugs	 are	 primarily	 used	 for	 the	
treatment	 of	 epilepsy,	 bipolar	 disorder	 [5‐7],	 trigeminal	
neuralgia	 [8],	 and	 other	 neurological	 disorders	 [9].	 Sulphon‐
amides	represent	an	important	class	of	medicinally	important	
molecules	 and	 are	 known	 to	 possess	 wide	 varieties	 of	
biological	 activities,	 hence	 sulphonamides	 moieties	 are	 an	
integral	part	of	many	antimicrobial	drugs,	saluretics,	carbonic	
anhydrase	 inhibitors,	 antithyroid	 agents,	 antitumour	 drugs,	
etc.	 [10‐19].	 Sulphonamides	 remain	 the	 most	 widely	 used	
antibacterial	agents	in	the	world	because	of	their	low	cost,	low	
toxicity	 and	 excellent	 activity	 against	 common	 bacterial	
diseases.	
 	
Figure	 1. Some	 pharmaceutically	 important	 structure	 of	 5H‐dibenz[b,f]	
azepine	(1)	and	its	analogues	(1a and	b).	
	
Recently,	 we	 have	 reported	 the	 synthesis	 and	 the	
antioxidant	 properties	 of	 5H‐dibenz[b,f]azepine	 analogues	
functionalized	with	 amino	 acids	 (1c)	 and	 aminophenols	 (1d)	
(Figure	2)	[20,21].	The	literature	survey	approaching	towards	
synthesis	of	sulphonamide	linked	pyrazole	gathered	with	5H‐
dibenz[b,f]azepine	 moiety	 indicates	 the	 lack	 of	 reference	
available.		
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Figure	2.	5H‐Dibenz[b,f]azepine	analogues	functionalized	with	amino	acids	
(1c)	and	aminophenols	(1d).	
	
In	 view	 of	 these	 observation	 and	 in	 persistence	 of	 our	
earlier	 work	 on	 different	 bioactive	 heterocyclic	 derivatives	
[22‐26],	 we	 envision	 our	 approach	 towards	 gathering	 two	
bioactive	 entities,	 5H‐dibenz[b,f]azepine	 and	 pyrazole	
sulphonamide	 in	 one	 compact	 structure	 for	 probing	 the	
antimicrobial	and	antioxidant	potentials.	
	
2.	Experimental	
	
2.1.	Materials	and	methods		
	
All	 reagents	 and	 solvents	 were	 purchased	 from	 Merck	
(Darmstadt,	 Germany)	 chemical	 AR	 grade	 and	 were	 used	 as	
provided.	1	1‐diphenyl‐2‐picrylhydrazyl	(DPPH)	and	butylated	
hydroxy	 anisole	 (BHA)	 were	 purchased	 from	 Sigma‐Aldrich	
chemical	Co.	(St.	Louis,	MO,	USA).	TLC	analysis	was	performed	
on	 alumina	 sheets	 precoated	with	 silica	 gel	 60F254	 and	 SiO2,	
150	mesh	 (Merck)	was	 used	 for	 column	 chromatography.	 1H	
NMR	 (400	 MHz)	 and	 13C	 NMR	 (100	 MHz)	 spectra	 were	
recorded	 on	 Bruker	 spectrometer	 in	 the	 appropriate	
deuterated	 dimethyl	 sulphoxide	 (DMSO‐d6)	 solvent.	 Melting	
points	were	obtained	on	a	Reichert	 thermopan	melting	point	
apparatus,	 equipped	with	 a	microscope	 and	 are	 uncorrected.	
Mass	 spectra	 were	 obtained	 by	 Water‐Q‐TOF	 ultima	
spectrometer.	 Micro	 analytical	 data	 were	 obtained	 by	
Elemental‐Vario	EL‐III.	
	
2.2.	Synthesis		
	
2.2.1.	Procedure	for	synthesis	of	4‐(5H‐dibenzo[b,f]azepin‐
5‐yl)benzaldehyde	(3)	
	
The	 mixure	 of	 4‐chlorobenzaldehyde	 (2)	 (0.8	 mol)	 was	
refluxed	 at	 65	 °C	 in	 the	 appropriate	 amount	 of	 5H‐dibenzo	
[b,f]azepine	(1)	(0.8	mol)	 for	4	hrs.	The	progress	of	 the	reac‐
tion	 was	 monitored	 by	 using	 TLC.	 After	 completion	 of	 the	
reaction,	 the	reaction	mass	was	poured	on	ice	cold	water	(50	
mL)	 to	 give	 white	 solid	 precipitate	 which	 was	 then	 filtered,	
dried	 and	 recrystallized	 in	 ethanol	 to	 give	 the	 pure	 solid	
product	(3)	(Scheme	1).	
4‐(5H‐Dibenzo[b,f]azepin‐5‐yl)benzaldehyde	 (3):	 Color:	
Yellow	solid.	Yield:	66%.	M.p:	124‐125	°C.	FT‐IR	(KBr,	,	cm‐1):	
2900‐2700	 (Ar‐H),	1701	 (C=O).	 1H	NMR	(400	MHz,	DMSO‐d6,	
δ,	ppm):	10.1	(s,	1H,	CHO),	6.99	(s,	2H,	Azepine‐H),	6.86‐7.34	
(m,	12H,	Ar‐H).	 13C	NMR	(100	MHz,	DMSO‐d6,	 δ,	ppm):	190.8	
(1C,	CHO),	150.1	(1C,	C‐N),	137‐119	(19C,	Ar‐C).	MS	(ESI,	m/z	
(%)):	297.11	(M+,	100).	Anal.	calcd.	 for	C21H15NO:	C,	84.82;	H,	
5.08;	N,	4.71.	Found:	C,	84.63;	H,	4.99;	N,	4.51%.	
(E)‐3‐(4‐(5H‐Dibenz[b,	 f]azepin‐5‐yl)phenyl)‐1‐phenylprop‐
2‐en‐1‐one	 (7):	 Color:	 Yellow	 solid.	 Yield:	 88%.	M.p:	 164‐167	
°C.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	 3131‐2973	 (Ar‐CH),	 1705	 (C=O).	 1H	
NMR	(400	MHz,	DMSO‐d6,	δ	ppm):	8.06	(d,	1H,	beta‐H),	6.63‐
7.89	 (m,	 17H,	 Ar‐Hs),	 6.99	 (s,	 2H,	 Azepine‐H),	 7.59	 (d,	 1H,	
Alpha‐H).	 13C	 NMR	 (100	 MHz,	 DMSO‐d6,	 δ,	 ppm):	 189.7	 (1C,	
C=O),	 145.1,	 137.9,	 137.8,	 134.5,	 132.0,	 131.1,	 129.7,	 129.6,	
129.5,	129.2,	128.8,	128.5,	124.9,	123.0,	121.3,	119.3	(28C,	Ar‐
C).	 MS	 (ESI,	 m/z	 (%)):	 399.16	 (M+,	 100).	 Anal.	 calcd.	 for	
C29H21NO,	C,	87.19;	H,	5.30;	N,	3.51.	Found:	C,	87.15;	H,	5.36;	N,	
3.53%.	
(E)‐3‐(4‐(5H‐Dibenz[b,	 f]azepin‐5‐yl)phenyl)‐1‐(4‐hydroxy	
phenyl)prop‐2‐en‐1‐one	 (8):	 Color:	 Yellow	 solid.	 Yield:	 65%.	
M.p:	 180‐183	 °C.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	 3139‐2970	 (Ar‐CH),	
1704	 (C=O),	 3602	 (OH)	 (Phenolic‐OH).	 1H	 NMR	 (400	 MHz,	
DMSO‐d6,	δ	ppm):	10.2	(s,	1H,	OH),	8.06	(d,	1H,	beta‐H),	6.63‐
8.05	 (m,	 16H,	 Ar‐Hs),	 6.99	 (s,	 2H,	 azepine‐H),	 7.59	 (d,	 1H,	
Alpha‐H),	 5.35	 (s,	 1H,	 O‐H).	 13C	 NMR	 (100	MHz,	 DMSO‐d6,	 δ,	
ppm):	164.3	(1C,	C=O),	145.1,	137.8,	132.0,	131.3,	131.1,	130.5,	
129.7,	 129.6,	 129.5,	 128.8,	 124.9,	 123.0,	 121.3,	 119.3,	 116.4	
(28C,	 Ar‐C).	MS	 (ESI,	m/z	 (%)):	 415.16	 (M+).	 Anal.	 calcd.	 for	
C29H21NO2,	C,	83.83;	H,	5.09;	N,	3.37.	Found:	C,	83.86;	H,	5.06;	
N,	3.33%.	
(E)‐3‐(4‐(5H‐Dibenz[b,	 f]azepin‐5‐yl)phenyl)‐1‐(4‐chloro	
phenyl)prop‐2‐en‐1‐one	 (9):	 Color:	 Yellow	 solid.	 Yield:	 55%.	
M.p:	 185‐188	 °C.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	 3136‐2972	 (Ar‐CH),	
1706	(C=O),	3045	(Ar‐CH),	3605	(OH)	(Phenolic‐OH),	813	(C‐
Cl),	1361	(C‐N).	1H	NMR	(400	MHz,	DMSO‐d6,	δ	ppm):	8.06	(d,	
1H,	Beta‐H),	 7.59	 (d,	 1H,	Alpha‐H),	 6.63‐7.65	 (m,	 16H,	Ar‐H),	
6.99	(s,	2H,	Azepine‐H).	13C	NMR	(100	MHz,	DMSO‐d6,	δ,	ppm):	
189.5	(1C,	C=O),	145.1,	140.3,	137.8,	136.0,	132.0,	131.2,	130.3,	
129.5,	 129.3,	 128.8,	 124.7,	 123.0,	 122.4,	 122.8,	 121.3,	 119.0	
(C28,	 Ar‐C).	MS	 (ESI,	m/z	 (%)):	 433.12	 (M+).	 Anal.	 calcd.	 for	
C29H20ClNO,	C,	80.27;	H,	4.65;	N,	3.23.	Found:	C,	80.20;	H,	4.60;	
N,	3.21%.	
	
2.2.2.	Procedure	for	synthesis	of	5H‐dibenz[b,f]aIzepine	
based	pyrazoles	(10‐12)	via	cyclization	of	compound	7‐9	
with	hydrazine	hydrate		
	
Hydrazine	 hydrate	 (10	 mmol)	 was	 added	 to	 a	 round	
bottom	flask	containing	5	mL	ethanolic	solution	of	compound	
7‐9	(1	mmol).	The	reaction	mass	was	heated	at	reflux	for	3	hrs	
and	 glacial	 acetic	 acid	 (1	 mmol)	 was	 added.	 Heating	 was	
continued	 for	 2	 hrs.	 After	 completion	 of	 the	 reaction	
(monitored	by	TLC),	the	reaction	mixture	was	cooled	to	room	
temperature.	 At	 the	 end,	 10	 mL	 of	 cold	 water	 was	 slowly	
added	to	the	flask.	The	separated	product	was	filtered	off	and	
washed	 with	 cold	 water	 for	 several	 times.	 The	 final	
compounds	10‐12	were	 recrystallized	 from	 ethanol	 (Scheme	
1).	
5‐(4‐(3‐Phenyl‐4,	 5‐dihydro‐1H‐pyrazol‐5‐yl)phenyl)‐5H‐
dibenz[b,f]azepine	(10):	 Color:	 Yellow	 solid.	 Yield:	 74%.	 M.p:	
206‐209	 °C.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	 3059‐2985	 (Ar‐CH),	 3352	
(NH),	 1624	 (C=N,	 Pyrazole),	 1366	 (C‐N).	 1H	NMR	 (400	MHz,	
DMSO‐d6,	δ	ppm):	6.63‐7.67	(m,	17H,	Ar‐Hs),	7.10	(d,	1H,	N‐H),	
6.99	 (s,	2H,	Azepine‐H),	3.69	 (d,	2H,	Pyrazzole	alpha‐H),	3.90	
(m,	 1H,	 Pyrazzole	 beta‐H).	 13C	 NMR	 (100	 MHz,	 DMSO‐d6,	 δ,	
ppm):	151.7	(1C,	C=N),	143.9,	137.9,	137.8,	136.4,	132.0,	131.1,	
131.0,	129.5,	129.2,	128.8,	128.2,	127.8,	123.0,	119.3	(26C,	Ar‐
C),	51.1	(1C,	C‐CN)	(Pyrole),	42.6	(1C,	CH2)	(Pyrole).	MS	(ESI,	
m/z	 (%)):	 413.19	 (M+).	 Anal.	 calcd.	 for	 C29H23N3,	 C,	 84.23;	 H,	
5.61;	N,	10.16.	Found:	C,	84.25;	H,	5.63;	N,	10.15%.	
4‐(5‐(4‐(5H‐Dibenz[b,f]azepin‐5‐yl)phenyl)‐4,5‐dihydro‐1H‐
pyrazol‐3‐yl)phenol	 (11):	Color:	Brown	solid.	Yield:	56%.	M.p:	
190‐193	 °C.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	 3049‐2972	 (Ar‐CH),	 3602	
(OH),	3356	 (NH),	 1628	 (C=N,	Pyrazole),	 1359	 (C‐N).	 1H	NMR	
(400	MHz,	DMSO‐d6,	 δ	 ppm):	 10.2	 (s,	 1H,	 OH),	 6.63‐7.85	 (m,	
16H,	Ar‐H),	7.15	(s,	1H,	N‐H),	6.99	(s,	2H,	Azepine‐H),	3.74	(d,	
2H,	Pyrazole	alpha‐H),	3.85	(m,	1H,	Pyrazole	beta‐H).	13C	NMR	
(100	MHz,	DMSO‐d6,	 δ,	ppm):	160.8	 (1C,	C‐OH),	151.7,	143.9,	
137.9,	 132.0,	 131.1,	 129.5,	 129.2,	 129.1,	 129.0,	 128.8,	 127.8,	
123.0,	 119.3,	 116.0	 (26C,	 Ar‐C),	 51.1	 (1C,	 C‐NH)	 (Pyrazole),	
42.6	(1C,	CH2).	MS	(ESI,	m/z	(%)):	429.18	(M+).	Anal.	calcd.	for	
C29H23N3O,	C,	81.09;	H,	5.40;	N,	9.78.	Found:	C,	81.06;	H,	5.42;	
N,	9.77%.		
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5‐(4‐(3‐(4‐Chlorophenyl)‐4,	 5‐dihydro‐1H‐pyrazol‐5‐yl)	
phenyl)‐5H‐dibenz[b,f]azepine	(12):	 Color:	 Light	 brown	 solid.	
Yield:	72%.	M.p:	182‐185	°C.	FT‐IR	(KBr,	ν,	cm‐1):	3345	(NH),	
3045‐2896	(Ar‐CH),	1635	(C=N,	Pyrazole),	1364	(C‐N),	813	(C‐
Cl).	 1H	NMR	(400	MHz,	DMSO‐d6,	 δ	ppm):	7.98‐6.63	 (m,	16H,	
Ar‐H),	 7.10	 (s,	 1H,	NH),	 6.99	 (s,	 2H,	 Azepine‐H),	 3.94	 (d,	 2H,	
Pyrazole	 Alpha‐H),	 3.93	 (m,	 1H,	 Pyrazole	 Beta‐H).	 13C	 NMR	
(100	 MHz,	 DMSO‐d6,	 δ,	 ppm):	 151.7	 (1C,	 C=N)	 (Pyrazole),	
151.0	(1C,	C‐N),	145.9,	143.9,	137.9,	137.8,	132.0,	131.2,	131.1,	
129.5,	 129.2,	 128.8,	 127.8,	 124.6,	 123.0,	 122.9,	 119.3,	 115.5	
(25C,	 Ar‐C)	 (aromatic),	 51.5	 (1C,	 C‐NH)	 (Pyrazole),	 42.1	 (1C,	
CH2)	 (Pyrazole).	MS	 (ESI,	m/z	 (%)):	 447.15	 (M+).	Anal.	 calcd.	
for	 C29H22ClN3,	 C,	 77.76;	H,	 4.95;	N,	 9.38.	 Found:	 C,	 77.70;	H,	
4.91;	N,	9.42%.		
	
2.2.3.	General	procedure	for	synthesis	of	5H‐dibenz[b,f]	
azepine	based	pyrazole	sulphanamides	(20‐40)	
	
To	a	well	stirred	solution	of	compounds	10‐12	(1	mmol)	in	
5‐10	 mL	 of	 dry	 tetrahydrofuran	 (THF),	 triethylamine	 (TEA)	
(1.2	 mmol)	 was	 added	 slowly	 and	 stirred	 for	 4	 h	 at	 room	
temperature.	 After	 completion	 of	 the	 reaction,	 the	 reaction	
mixture	 was	 quenched	 with	 ice	 cold	 water	 and	 the	 product	
was	 extracted	 in	 dichloromethane	 (DCM).	 The	organics	were	
washed	 with	 sodium	 bicarbonate	 (Na2HCO3)	 and	 dried	 over	
anhydrous	sodium	sulphate	(Na2SO4)	and	concentrated	under	
rota	evaporator	to	get	desired	products	20‐40	(Scheme	1).		
5‐(4‐(3‐Phenyl‐1‐(phenylsulfonyl)‐4,	 5‐dihydro‐1H‐pyrazol‐
5‐yl)phenyl)‐5H‐dibenz[b,f]azepine	 (20):	 Color:	 Green	 solid.	
Yield:	75%.	M.p:	248‐251	°C.	FT‐IR	 (KBr,	ν,	 cm‐1):	3124‐2981	
(Ar‐CH),	1624	(C=N,	Pyrazole),	1353	(C‐N).	1H	NMR	(400	MHz,	
DMSO‐d6,	 δ	 ppm):	 6.58‐7.67	 (m,	 24H,	 Ar‐Hs),	 3.90	 (d,	 2H,	
Pyrazole	CH2),	4.1	(m,	1H,	CH).	13C	NMR	(100	MHz,	DMSO‐d6,	δ,	
ppm):	151.5	 (1C,	C=N)	 (Pyrazole),	 144.4,	143.5,	137.9,	137.6,	
136.4,	 132.0,	 131.5,	 131.0,	 129.5,	 129.1,	 128.8,	 128.2,	 127.8,	
127.3,	 123.0,	 119.3	 (32C,	 Ar‐C)	 (aromatic),	 49.5	 (1C,	 C‐N)	
(Pyrazole),	 39.0	 (1C,	 CH2)	 (Pyrazole).	 MS	 (ESI,	 m/z	 (%)):	
553.18	(M+).	Anal.	calcd.	for	C35H27N3O2S,	C,	75.92;	H,	4.92;	N,	
7.59;	O,	5.78;	S,	5.79;	found:	C,	75.90;	H,	4.89;	N,	7.66;	O,	5.73;	
S,	5.83%.		
4‐(5‐(4‐(5H‐Dibenz[b,	 f]azepin‐5‐yl)phenyl)‐3‐phenyl‐4,	 5‐
dihydro‐1H‐pyrazol‐1‐ylsulfonyl)phenol	 (21):	Color:	Green	 solid.	
Yield:	77%.	M.p:	235‐238	°C.	FT‐IR	 (KBr,	ν,	 cm‐1):	3097‐2973	
(Ar‐CH),	1628	(C=N,	Pyrazole),	1362	(C‐N).	1H	NMR	(400	MHz,	
DMSO‐d6,	 δ	 ppm):	 6.58‐7.67	 (m,	 21H,	 Ar‐H),	 6.99	 (s,	 2H,	
Azepine‐H),	 5.32	 (s,	 1H,	 OH),	 3.95	 (m,	 1H,	 Pyrazole	 beta‐H),	
3.69	(d,	2H,	Pyrazole	alpha‐H).	13C	NMR	(100	MHz,	DMSO‐d6,	δ,	
ppm):	143.8	(1C,	C‐OH),	141.2	(Pyrazole),	138.4,	138.0,	137.8,	
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136.1,	 132.0,	 131.4,	 131.3,	 152.0,	 129.5,	 129.3,	 129.0,	 128.8,	
128.3,	 127.5,	 123.0,	 119.0,	 49.3	 (31C,	 Ar‐C),	 39.0	 (1C,	 C‐N)	
(Pyrzole),	21.3	(1C,	CH2)	(Pyrazole).	MS	(ESI,	m/z	(%)):	569.18	
(M+).	 Anal.	 calcd.	 for	 C35H27N3O3S,	 C,	 73.79;	 H,	 4.78;	 N,	 7.38.	
Found:	C,	73.72;	H,	4.73;	N,	7.35%.	
2‐(5‐(4‐(5H‐Dibenz[b,	 f]azepin‐5‐yl)phenyl)‐3‐phenyl‐4,	 5‐
dihydro‐1H‐pyrazol‐1‐ylsulfonyl)phenol	 (22):	 Color:	 Green	
solid.	Yield:	55%.	M.p:	232‐236	°C.	FT‐IR	(KBr,	ν,	cm‐1):	3085‐
2970	(Ar‐CH),	1620	(C=N,	Pyrazole),	1368	(C‐N).	1H	NMR	(400	
MHz,	DMSO‐d6,	δ	ppm):	6.58‐7.65	(m,	21H,	Ar‐H),	6.93	(s,	2H,	
Azepine‐H),	 5.35	 (s,	 1H,	 OH),	 3.92	 (m,	 1H,	 Pyrazole	 beta‐H),	
3.65	(d,	2H,	Pyrazole	alpha‐H).	13C	NMR	(100	MHz,	DMSO‐d6,	δ,	
ppm):	 143.5	 (1C,	 C‐OH)	 (phenolic	 OH),	 141.0,	 138.5,	 138.0,	
137.8,	 136.0,	 132.3,	 131.4,	 131.0,	 152.0,	 129.5,	 129.3,	 129.0,	
128.8,	128.2,	127.3,	123.1,	119.3,	49.0	(32C,	C‐Ar)	(aromatic),	
39.2	 (1C,	C‐N)	 (Pyrazole),	 21.4	 (1C,	CH2)	 (Pyrazole).	MS	 (ESI,	
m/z	 (%)):	569.17	 (M+).	Anal.	 calcd.	 for	C35H27N3O3S,	C,	73.79;	
H,	4.78;	N,	7.38.	Found:	C,	73.74;	H,	4.82;	N,	7.44%.	
5‐(4‐(1‐(4‐Methoxyphenylsulfonyl)‐3‐phenyl‐4,	 5‐dihydro‐
1H‐pyrazol‐5‐yl)phenyl)‐5H‐dibenz[b,f]azepine	 (23):	 Color:	
Brown	solid.	Yield:	54%.	M.p:	165‐168	°C.	FT‐IR	(KBr,	ν,	cm‐1):	
3089‐2968	 (Ar‐CH),	 1625	 (C=N,	 Pyrazole),	 1374	 (C‐N).	 1H	
NMR	 (400	MHz,	DMSO‐d6,	 δ	 ppm):	 6.50‐7.62	 (m,	 21H,	Ar‐H),	
6.96	(s,	2H,	Azepine‐H),	3.92	(m,	1H,	Pyrazole	beta‐H),	3.83	(s,	
3H,	OCH3),	3.61	(d,	2H,	Pyrazole	alpha‐H).	13C	NMR	(100	MHz,	
DMSO‐d6,	δ,	ppm):	163.8	(1C,	C‐OMe)	(Aromatic	C‐OMe),	151.8	
(1C,	C=N)	(pyrazole),	143.9,	137.8,	137.5,	136.5,	136.0,	132.0,	
131.1,	 129.5,	 129.0,	 128.8,	 128.2,	 127.8,	 126.1,	 123.0,	 119.3,	
114.6	 (31C,	 Ar‐C),	 55.8	 (1C,	OCH3)	 (Methoxy),	 49.5	 (1C,	 C‐N)	
(Pyrazole),	 39.0	 (1C,	 CH2)	 (Pyrazole).	 MS	 (ESI,	 m/z	 (%)):	
583.19	(M+).	Anal.	calcd.	for	C36H29N3O3S,	C,	74.08;	H,	5.01;	N,	
7.20.	Found:	C,	74.12;	H,	4.95;	N,	7.23%.	
5‐(4‐(1‐(4‐Nitrophenylsulfonyl)‐3‐phenyl‐4,	 5‐dihydro‐1H‐
pyrazol‐5‐yl)phenyl)‐5H‐dibenz[b,f]azepine	 (24):	 Color:	 Green	
solid.	Yield:	63%.	M.p:	192‐194	°C.	FT‐IR	(KBr,	ν,	cm‐1):	3137‐
2971	 (Ar‐CH),	1632	 (C=N,	Pyrazole),	 1374	 (C‐N),	1562,	1346	
(N‐O).	1H	NMR	(400	MHz,	DMSO‐d6,	δ	ppm):	6.58‐8.39	(m,	21H,	
Ar‐H),	6.99	(s,	2H,	Azepine‐H),	3.72	(d,	2H,	Pyrazole	alpha‐H),	
3.95	(m,	1H,	Pyrazole	beta‐H).	13C	NMR	(100	MHz,	DMSO‐d6,	δ,	
ppm):	 151.7	 (1C,	 C=N)	 (Pyrazole),	 150.5	 (1C,	 C‐NO2)	 (Nitro	
phenol),	143.9,	137.4,	137.1,	135.9,	132.0,	131.4,	131.0,	129.6,	
129.1,	128.8,	128.3,	127.5,	124.4,	123.1,	119.2	(31C,	Ar‐C),	49.8	
(1C,	 C‐N)	 (Pyrazole),	 39.2	 (1C,	 CH2)	 (Pyrazole).	MS	 (ESI,	m/z	
(%)):	 598.17	 (M+).	 Anal.	 calcd.	 for	 C35H26N4O4S,	 C,	 70.22;	 H,	
4.38;	N,	9.36.	Found:	C,	70.20;	H,	4.34;	N,	9.34%.	
5‐(4‐(1‐(4‐Bromophenylsulfonyl)‐3‐phenyl‐4,5‐dihydro‐1H‐
pyrazol‐5‐yl)phenyl)‐5H‐dibenz[b,f]azepine	 (25):	 Color:	 Green	
solid.	Yield:	91%.	M.p:	172‐174	°C.	FT‐IR	(KBr,	ν,	cm‐1):	3045‐
2854	 (Ar‐CH),	 1371	 (C‐N).	 1H	 NMR	 (400	 MHz,	 DMSO‐d6,	 δ	
ppm):	6.58‐7.80	(m,	21H,	Ar‐H),	6.99	(s,	2H,	Azepine‐H),	3.90	
(m,	 1H,	 Pyrazole	 beta‐H),	 3.72	 (d,	 2H,	 Pyrazole	 alpha‐H).	 13C	
NMR	(100	MHz,	DMSO‐d6,	δ,	ppm):	151.9	(1C,	C=N)	(Pyrazole),	
143.9,	 142.5,	 137.9,	 137.8,	 137.6,	 136.4,	 132.8,	 132.4,	 131.6,	
129.5,	 129.2,	 129.0,	 128.9,	 128.7,	 128.2,	 127.4,	 123.0,	 119.3	
(32C,	 Ar‐C),	 49.5	 (1C,	 C‐N)	 (Pyrazole),	 38.9	 (1C,	 CH2)	
(Pyrazole).	 MS	 (ESI,	m/z	 (%)):	 631.09	 (M+).	 Anal.	 calcd.	 for	
C35H26BrN3O2S,	 C,	 66.46;	H,	 4.14;	N,	 6.64.	 Found:	 C,	 66.42;	H,	
4.10;	N,	6.60%.	
5‐(4‐(3‐Phenyl‐1‐tosyl‐4,	 5‐dihydro‐1H‐pyrazol‐5‐yl)phenyl)‐
5H‐dibenz[b,f]azepine	 (26):	 Color:	Green	 solid.	 Yield:	 58.90%.	
M.p:	 187‐189	 °C.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	 3097‐2973	 (Ar‐CH),	
1628	(C=N,	Pyrazole),	1362	(C‐N).		1H	NMR	(400	MHz,	DMSO‐
d6,	δ	ppm):	6.58‐7.67	(m,	21H,	Ar‐H),	6.99	(s,	2H,	Azepine‐H),	
3.95	(m,	1H,	Pyrazole	beta‐H),	3.69	(d,	2H,	Pyrazole	alpha‐H),	
2.34	(s,	3H,	CH3).	13C	NMR	(100	MHz,	DMSO‐d6,	δ,	ppm):	143.8	
(1C,	C=N)	(Pyrazole),	141.2,	138.4,	138.0,	137.8,	136.1,	132.0,	
131.4,	 131.3,	 152.0,	 129.5,	 129.3,	 129.0,	 128.8,	 128.3,	 127.5,	
123.0,	119.0	(32C,	Ar‐C),	49.3	(1C,	C‐N)	(Ppyrazole),	39.0	(1C,	
CH2)	 (Pyrazole),	 21.3	 (1C,	 CH3)	 (Methyl).	MS	 (ESI,	m/z	 (%)):	
567.20	(M+).	Anal.	calcd.	for	C36H29N3O2S,	C,	76.16;	H,	5.15;	N,	
7.40.	Found:	C,	76.14;	H,	5.19;	N,	7.43%.		
4‐(5‐(4‐(5H‐Dibenz[b,	 f]azepin‐5‐yl)phenyl)‐1‐(phenyl	
sulfonyl)‐4,	 5‐dihydro‐1H‐pyrazol‐3‐yl)phenol	 (27):	 Color:	
Reddish	brown	solid.	Yield:	63%.	M.p.:	240‐243	°C.	FT‐IR	(KBr,	
ν,	cm‐1):	3042‐2774	(Ar‐CH),	3602	(OH),	1641	(C=N,	Pyrazole),	
1360	 (C‐N).	 1H	 NMR	 (400	MHz,	 DMSO‐d6,	 δ	 ppm):	 6.55‐7.85	
(m,	21H,	Ar‐H),	6.95	(s,	2H,	Azepine‐H),	5.35	(s,	1H,	OH),	3.95	
(m,	 1H,	 Pyrazole	 beta‐H),	 3.62	 (d,	 2H,	 Pyrazole	 alpha‐H).	 13C	
NMR	 (100	 MHz,	 DMSO‐d6,	 δ,	 ppm):	 160.7	 8	 (1C,	 C‐OH)	
(phenolic	OH),	151.8	(1C,	C=N)	(Pyrazole),	144.2,	143.5,	137.5,	
132.0,	 131.5,	 131.0,	 129.5,	 129.2,	 129.0,	 128.8,	 127.6,	 127.3,	
123.0,	119.3,	116.0,	49.3	(32C,	Ar‐C),	38.7	(1C,	CH2).	MS	(ESI,	
m/z	 (%)):	569.17	 (M+).	Anal.	 calcd.	 for	C35H27N3O3S,	C,	73.79;	
H,	4.78;	N,	7.38.	Found:	C,	73.75;	H,	4.83;	N,	7.42%.	
4‐(5‐(4‐(5H‐Dibenzo[b,	 f]azepin‐5‐yl)phenyl)‐1‐(4‐hydroxy	
phenylsulfonyl)‐4,5‐dihydro‐1H‐pyrazol‐3‐yl)phenol	(28):	Color:	
Green	 semisolid.	 Yield:	 80.30%.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	 3038‐
2770	 (Ar‐CH),	 3585	 (OH),	 1638	 (C=N,	Pyrazole),	 1372	 (C‐N).	
1H	NMR	 (400	MHz,	DMSO‐d6,	 δ	ppm):	6.58‐7.85	 (m,	20H,	Ar‐
H),	 6.90	 (s,	 2H,	 Azepine‐H),	 5.33	 (s,	 2H,	 OH),	 3.92	 (m,	 1H,	
Pyrazole	beta‐H),	3.65	(d,	2H,	Pyrazole	alpha‐H).	13C	NMR	(100	
MHz,	 DMSO‐d6,	 δ,	 ppm):	 161.5	 8	 (1C,	 C‐OH)	 (Phenolic	 OH),	
160.7	(Phenolic	OH),	151.5	(1C,	C=N)	(Pyrazole),	143.5,	137.8,	
137.5,	 137.0,	 132.0,	 131.0,	 130.0,	 129.5,	 129.2,	 129.0,	 128.8,	
127.7,	126.6,	123.3,	119.2,	116.0	(30C,	Ar‐C),	49.6	3	(1C,	C‐N),	
39.3	 (1C,	 CH2)	 (Pyrazole).	 MS	 (ESI,	 m/z	 (%)):	 585.17	 (M+).	
Anal.	calcd.	for	C35H27N3O4S,	C,	71.78;	H,	4.65;	N,	7.17.	Found:	C,	
71.73;	H,	4.60;	N,	7.23%.	
2‐(5‐(4‐(5H‐Dibenz[b,	 f]azepin‐5‐yl)phenyl)‐3‐(4‐hydroxy	
phenyl)‐4,5‐dihydro‐1H‐pyrazol‐1‐ylsulfonyl)phenol	(29):	Color:	
Light	yellow	solid.	Yield:	66%.	M.p:	199‐202	°C.	FT‐IR	(KBr,	ν,	
cm‐1):	 3030‐2778	 (Ar‐CH),	 3583	 (OH),	 1642	 (C=N,	 Pyrazole),	
1370	 (C‐N).	 1H	 NMR	 (400	MHz,	 DMSO‐d6,	 δ	 ppm):	 6.55‐7.83	
(m,	20H,	Ar‐H),	6.89	(s,	2H,	Azepine‐H),	5.35	(s,	2H,	OH),	3.95	
(m,	 1H,	 Pyrazole	Beta‐H),	 3.66	 (d,	 2H,	Pyrazole	Alpha‐H).	 13C	
NMR	 (100	 MHz,	 DMSO‐d6,	 δ,	 ppm):	 161.8	 8	 (1C,	 C‐OH)	
(Phenolic	 OH),	 160.8	 8	 (1C,	 C‐OH)	 (Phenolic	 OH),	 151.3	 (1C,	
C=N)	 (Pyrazole),	 143.4,	 137.5,	 137.6,	 137.1,	 131.9,	 131.3,	
130.0,	 129.8,	 129.1,	 129.0,	 128.8,	 127.8,	 126.5,	 123.0,	 119.3,	
116.3	(30C,	Ar‐H),	49.5	(1C,	C‐N),	39.5	(1C,	CH2)	(Pyrazole).	MS	
(ESI,	m/z	 (%)):	 585.18	 (M+).	 Anal.	 calcd.	 for	 C35H27N3O4S,	 C,	
71.78;	H,	4.65;	N,	7.17.	Found:	C,	71.82;	H,	4.69;	N,	7.15%.	
4‐(5‐(4‐(5H‐Dibenz[b,	 f]azepin‐5‐yl)phenyl)‐1‐(4‐methoxy	
phenylsulfonyl)‐4,5‐dihydro‐1H‐pyrazol‐3‐yl)phenol	(30):	Color:	
Yellow	solid.	Yield:	67%.	M.p:	205‐207	°C.	FT‐IR	(KBr,	ν,	cm‐1):	
3035‐2770	 (Ar‐CH),	 3589	 (O‐H),	 1651	 (C=N,	Pyrazole),	 1365	
(C‐N).	 1H	 NMR	 (400	 MHz,	 DMSO‐d6,	 δ,	 ppm):	 6.58‐7.86	 (m,	
20H,	 Ar‐H),	 6.89	 (s,	 2H,	 Azepine‐H),	 3.98	 (m,	 1H,	 Pyrazole	
beta‐H),	3.84	(s,	3H,	OCH3),	3.68	(d,	2H,	Pyrazole	alpha‐H),	10.2	
(s,	1H,	OH).	13C	NMR	(100	MHz,	DMSO‐d6,	δ,	ppm):	163.7	(1C,	
C‐OMe)	(Aromatic	C‐OMe),	160.5	8	(1C,	C‐OH)	(Phenolic	OH),	
151.8	 (1C,	C=N)	 (Pyrazole),	144.0,	138.2,	137.8,	136.5,	132.5,	
131.1,	 129.5,	 129.0,	 128.9,	 128.7,	 127.5,	 126.0,	 123.0,	 119.5,	
116.2,	114.0	(30C,	Ar‐H),	55.8	(1C,	OCH3)	(Methoxy),	49.6,	39.0	
(1C,	 CH2)	 (Pyrazole).	 MS	 (ESI,	m/z	 (%)):	 599.18	 (M+).	 Anal.	
calcd.	 for	 C36H29N3O4S,	 C,	 72.10;	 H,	 4.87;	 N,	 7.01.	 Found:	 C,	
72.10;	H,	4.87;	N,	7.01%.	
4‐(5‐(4‐(5H‐Dibenz[b,f]azepin‐5‐yl)phenyl)‐1‐(4‐nitrophenyl	
sulfonyl)‐4,	 5‐dihydro‐1H‐pyrazol‐3‐yl)phenol	 (31):	 Color:	
Brown	solid.	Yield:	64%.	M.p:	224‐226	°C.	FT‐IR	(KBr,	ν,	cm‐1):	
3110‐2693	(Ar‐CH),	3602	(OH),	1562,	1346	(N‐O),	1641	(C=N	
Pyrazole),	 1360	 (C‐N).	 1H	NMR	 (400	MHz,	DMSO‐d6,	 δ	 ppm):	
6.58‐8.39	(m,	20H,	Ar‐H),	6.97	(s,	2H,	Azepine‐H),	5.35	(s,	1H,	
O‐H),	 3.93	 (m,	 1H,	 Pyrazole	 beta‐H),	 3.65	 (d,	 2H,	 Pyrazole	
alpha‐H).	 13C	NMR	(100	MHz,	DMSO‐d6,	δ,	ppm):	160.8	8	(1C,	
C‐OH)	 (phenolic	 OH),	 151.1	 (1C,	 C=N)	 (Pyrazole),	 150.5	 (1C,	
C=N)	 (pyrazole),	 143.8,	 138.0,	 137.8,	 132.0,	 131.3,	 129.6,	
129.2,	 129.1,	 129.0,	 128.8,	 128.4,	 127.2,	 124.2,	 123.0,	 119.6,	
116.4	(30C,	Ar‐C),	49.6	(1C,	C‐N),	39.2	(1C,	CH2)	(Pyrazole).	MS	
(ESI,	m/z	 (%)):	 614.16	 (M+).	 Anal.	 calcd.	 for	 C35H26N4O5S,	 C,	
68.39;	H,	4.26;	N,	9.11.	Found:	C,	68.37;	H,	4.25;	N,	9.14%.	
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4‐(5‐(4‐(5H‐Dibenz[b,	f]azepin‐5‐yl)phenyl)‐1‐(4‐bromo	
phenylsulfonyl)‐4,5‐dihydro‐1H‐pyrazol‐3‐yl)phenol	(32):	Color:	
Green	semisolid.	Yield:	88%.	FT‐IR	 (KBr,	 ν,	 cm‐1):	 3129‐2977	
(Ar‐CH),	3607(O‐H)	1638	(C=N,	Pyrazole),	1358	(C‐N),	858	(C‐
Br).	 1H	NMR	(400	MHz,	DMSO‐d6,	δ	ppm):	6.58‐7.90	(m,	20H,	
Ar‐H),	6.97	 (s,	2H,	Azepine‐H),	5.35	 (s,	 1H,	OH),	3.94	 (m,	1H,	
Pyrazole	beta‐H),	3.73	(d,	2H,	Pyrazole	alpha‐H).	13C	NMR	(100	
MHz,	 DMSO‐d6,	 δ,	 ppm):	 160.8	 8	 (1C,	 C‐OH)	 (Phenolic	 OH),	
151.7	 (1C,	C=N)	 (Pyrazole),	143.9,	142.6,	137.8,	137.4,	132.6,	
131.1,	 130.5,	 129.9,	 129.6,	 129.3,	 128.9,	 128.7,	 127.6,	 123.1,	
119.1,	 116.0	 (31C,	 Ar‐C),	 49.2	 (1C,	 C‐N),	 38.7	 (1C,	 CH2)	
(Pyrazole).	 MS	 (ESI,	m/z	 (%)):	 647.08	 (M+).	 Anal.	 calcd.	 for	
C35H26BrN3O3S,	 C,	 64.82;	H,	 4.04;	N,	 6.48.	 Found:	 C,	 64.80;	H,	
4.10;	N,	6.45%.	
4‐(5‐(4‐(5H‐Dibenz[b,	f]azepin‐5‐yl)phenyl)‐1‐(m‐tolylsulfon	
yl)‐4,	 5‐dihydro‐1H‐pyrazol‐3‐yl)phenol	 (33):	 Color:	 Brown	
solid.	Yield:	62%.	M.p:	203‐205	°C.	FT‐IR	(KBr,	ν,	cm‐1):	3105‐
2879	(Ar‐CH),	3602	(O‐H),	1625	(C=N,	Pyrazole),	1374	(C‐N).	
1H	NMR	 (400	MHz,	DMSO‐d6,	 δ	ppm):	6.58‐7.85	 (m,	 20H,	Ar‐
H),	 6.94	 (s,	 2H,	 Azepine‐H),	 5.30	 (s,	 1H,	 O‐H),	 3.92	 (m,	 1H,	
Pyrazole	 beta‐H),	 3.75	 (d,	 2H,	 Pyrazole	 alpha‐H),	 2.34	 (s,	 3H,	
CH3).	 13C	NMR	 (100	MHz,	 DMSO‐d6,	 δ,	 ppm):	 160.4	 8	 (1C,	 C‐
OH)	 (Phenolic	OH),	 151.5	 (1C,	 C=N)	 (Pyrazole),	 143.8,	 141.4,	
138.0,	 137.8,	 137.6,	 132.0,	 131.1,	 129.5,	 129.2,	 129.0,	 128.5,	
128.0,	 127.6,	 123.0,	 119.1,	 116.0	 (31C,	 Ar‐C),	 49.2	 (1C,	 C‐N),	
39.0(1C,	CH2)	(Pyrazole),	21.3	(1C,	CH3)	(Methyl).	MS	(ESI,	m/z	
(%)):	 583.19	 (M+).	 Anal.	 calcd.	 for	 C36H29N3O3S,	 C,	 74.08;	 H,	
5.01;	N,	7.20.	Found:	C,	74.04;	H,	5.02;	N,	7.24%.		
5‐(4‐(3‐(4‐Chlorophenyl)‐1‐(phenylsulfonyl)‐4,	 5‐dihydro‐
1H‐pyrazol‐5‐yl)phenyl)‐5H‐dibenz[b,f]azepine	 (34):	 Color:	
Yellow	solid.	Yield:	71%.	M.p:	215‐217	°C.	FT‐IR	(KBr,	ν,	cm‐1):	
3136‐2969	 (Ar‐CH),	 2826	 (C‐H),	 1639	 (C=N,	 Pyrazole),	 1364	
(C‐N),	821	(C‐Cl).	 1H	NMR	(400	MHz,	DMSO‐d6,	δ	ppm):	6.58‐
7.25	 (m,	 21H,	 Ar‐Hs),	 6.85	 (s,	 2H,	 Azepine‐H),	 3.95	 (m,	 1H,	
Pyrazole	beta‐H),	3.81	(d,	2H,	Pyrazole	alpha‐H).	13C	NMR	(100	
MHz,	 DMSO‐d6,	 δ,	 ppm):	 151.5	 (1C,	 C=N)	 (Pyrazole),	 144.4,	
143.9,	 137.5,	 137.4,	 136.6,	 134.4,	 132.0,	 131.8,	 131.0,	 129.5,	
129.2,	 129.0,	 128.7,	 128.5,	 128.2,	 127.8,	 127.3,	 123.0,	 119.3	
(32C,	Ar‐C),	49.5	(1C,	C‐N),	39.2	(1C,	CH2)	(Pyrazole).	MS	(ESI,	
m/z	(%)):	587.14	(M+).	Anal.	calcd.	for	C35H26ClN3O2S,	C,	71.48;	
H,	4.46;	N,	7.14.	Found:	C,	71.55;	H,	4.39;	N,	7.10%.		
4‐(5‐(4‐(5H‐Dibenz[b,	 f]azepin‐5‐yl)phenyl)‐3‐(4‐chloro	
phenyl)‐4,5‐dihydro‐1H‐pyrazol‐1‐ylsulfonyl)phenol	(35):	Color:	
Brown	solid.	Yield:	80%.	M.p:	255‐257	°C.	FT‐IR	(KBr,	ν,	cm‐1):	
3130‐2965	 (Ar‐CH),	 2835	 (C‐H),	 1642	 (C=N,	 pyrazole),	 1368	
(C‐N),	835	(C‐Cl).	 1H	NMR	(400	MHz,	DMSO‐d6,	δ	ppm):	6.54‐
7.30	(m,	20H,	Ar‐H),	6.92	(s,	2H,	Azepine‐H),	5.35	(s,	1H,	OH),	
3.96	(m,	1H,	Pyrazole	beta‐H),	3.75	(d,	2H,	Pyrazole	alpha‐H).	
13C	 NMR	 (100	 MHz,	 DMSO‐d6,	 δ,	 ppm):	 161.	 8	 8	 (1C,	 C‐OH)	
(phenolic	OH),	151.8	(1C,	C=N)	(Pyrazole),	144.2,	143.5,	137.7,	
137.3,	 136.5,	 134.5,	 132.3,	 131.0,	 129.4,	 129.2,	 129.0,	 128.8,	
128.4,	128.0,	127.8,	127.2,	123.6,	119.0	 (32C,	Ar‐C),	49.8	 (1C,	
C‐N),	 39.3	 (1C,	 CH2)	 (Pyrazole).	 MS	 (ESI,	m/z	 (%)):	 603.14	
(M+).	Anal.	calcd.	 for	C35H26ClN3O3S,	C,	69.58;	H,	4.34;	N,	6.96.	
Found:	C,	69.62;	H,	4.38;	N,	6.92%.		
2‐(5‐(4‐(5H‐Dibenz[b,	 f]azepin‐5‐yl)phenyl)‐3‐(4‐chloro	
phenyl)‐4,5‐dihydro‐1H‐pyrazol‐1‐ylsulfonyl)phenol	(36):	Color:	
Green	solid.	Yield:	70%.	M.p:	273‐276	°C.	FT‐IR	(KBr,	ν,	cm‐1):	
3135‐2968	 (Ar‐CH),	 2842	 (C‐H),	 1637	 (C=N,	 Pyrazole),	 1375	
(C‐N),	838	(C‐Cl).	 1H	NMR	(400	MHz,	DMSO‐d6,	δ	ppm):	6.58‐
7.32	(m,	20H,	Ar‐H),	6.99	(s,	2H,	Azepine‐H),	5.32	(s,	1H,	OH),	
3.95	(m,	1H,	Pyrazole	beta‐H),	3.75	(d,	2H,	Pyrazole	alpha‐H).	
13C	 NMR	 (100	 MHz,	 DMSO‐d6,	 δ,	 ppm):	 161.	 3	 8	 (1C,	 C‐OH)	
(Phenolic	OH),	151.5	(1C,	C=N)	(Pyrazole),	144.0,	143.8,	137.9,	
137.4,	 136.8,	 134.5,	 132.2,	 131.4,	 129.4,	 129.1,	 129.0,	 128.7,	
128.4,	128.2,	127.4,	127.0,	123.6,	119.3	 (31C,	Ar‐C),	49.5	 (1C,	
C‐N),	 39.0	 (1C,	 CH2)	 (Pyrazole).	 MS	 (ESI,	m/z	 (%)):	 603.13	
(M+).	Anal.	calcd.	 for	C35H26ClN3O3S,	C,	69.58;	H,	4.34;	N,	6.96.	
Found:	C,	69.64;	H,	4.40;	N,	6.95%.	
5‐(4‐(3‐(4‐Chlorophenyl)‐1‐(4‐methoxyphenylsulfonyl)‐4,5‐
dihydro‐1H‐pyrazol‐5‐yl)phenyl)‐5H‐dibenz[b,	 f]azepine	 (37):	
Color:	Green	solid.	Yield:	71%.	M.p:	240‐242	°C.	FT‐IR	(KBr,	ν,	
cm‐1):	3138‐2972	 (Ar‐CH),	2838	(C‐H),	1651	(C=N,	Pyrazole),	
1373	 (C‐N),	 842	 (C‐Cl).1H	NMR	 (400	MHz,	DMSO‐d6,	 δ	 ppm):	
6.54‐7.30	(m,	20H,	Ar‐H),	6.92	(s,	2H,	Azepine‐H),	3.95	(m,	1H,	
Pyrazole	 beta‐H),	 3.83	 (s,	 3H,	 OCH3),	 3.78	 (d,	 2H,	 Pyrazole	
alpha‐H).	13C	NMR	(100	MHz,	DMSO‐d6,	δ,	ppm):	163.8	(1C,	C‐
OMe)	 (Aromatic	 C‐OMe),	 151.4	 (1C,	 C=N)	 (Pyrazole),	 144.4,	
143.1,	 137.8,	 137.4,	 136.7,	 134.4,	 132.6,	 131.4,	 129.3,	 129.1,	
129.0,	128.8,	128.4,	128.2,	127.5,	127.0,	123.6,	119.5	(32C	Ar‐
C),	55.8	(1C,	OCH3)	(Methoxy),	49.3,	39.0	(1C,	CH2)	(Pyrazole).	
MS	(ESI,	m/z	(%)):	617.15	(M+).	Anal.	calcd.	for	C36H28ClN3O3S,	
C,	69.95;	H,	4.57;	N,	6.80.	Found:	C,	70.03;	H,	4.62;	N,	6.17%.	
5‐(4‐(3‐(4‐Chlorophenyl)‐1‐(4‐nitrophenylsulfonyl)‐4,	 5‐
dihydro‐1H‐pyrazol‐5‐yl)phenyl)‐5H‐dibenz[b,	 f]azepin	 (38):	
Color:	Green	solid.	Yield:	78%.	M.p:	219‐221	°C.	FT‐IR	(KBr,	ν,	
cm‐1):	3128‐2970	(Ar‐CH),	815	(C‐Cl)	1568,	1344	(N‐O)	1637	
(C=N,	 Pyrazole),	 1359	 (C‐N).	 1H	 NMR	 (400	MHz,	 DMSO‐d6,	 δ	
ppm):	6.58‐8.39	(m,	20H,	Ar‐H),	6.97	(s,	2H,	Azepine‐H),	3.94	
(d,	 2H,	 Pyrazole	 alpha‐H),	 3.85	 (m,	 1H,	 Pyrazole	 beta‐H).	 13C	
NMR	(100	MHz,	DMSO‐d6,	δ,	ppm):	151.9	(1C,	C=N)	(Pyrazole),	
151.5,	 151.0,	 145.7,	 143.8,	 138.2,	 137.8,	 132.0,	 131.6,	 131.1,	
129.9,	 129.2,	 128.6,	 128.3,	 127.7,	 124.6,	 124.2,	 123.4,	 122.9,	
119.6,	 115.4	 (32C,	 Ar‐C),	 49.6	 (1C,	 C‐N),	 38.3	 (1C,	 CH2)	
(Pyrazole).	 MS	 (ESI,	m/z	 (%)):	 632.12	 (M+).	 Anal.	 calcd.	 for	
C35H25ClN4O4S,	 C,	 66.40;	 H,	 3.98;	 N,	 8.85.	 Found:	 C,	 66.45;	H,	
4.02;	N,	8.89%.	
5‐(4‐(1‐(4‐Bromophenylsulfonyl)‐3‐(4‐chlorophenyl)‐4,	 5‐
dihydro‐1H‐pyrazol‐5‐yl)phenyl)‐5H‐dibenz[b,	 f]azepine	 (39):	
Color:	Green	semisolid.	Yield:	64%.	FT‐IR	(KBr,	ν,	cm‐1):	3140‐
2961	(Ar‐CH),	1642	(C=N	Pyrazole),	1353	(C‐N),	829,	816	(C‐
Cl).	 1H	NMR	(400	MHz,	DMSO‐d6,	 δ	ppm):	6.58‐7.80	 (m,	20H,	
Ar‐H),	6.95	(s,	2H,	Azepine‐H),	3.95	(m,	1H,	Pyrazole	beta‐H),	
3.87	(d,	2H,	Pyrazole	alpha‐H).	13C	NMR	(100	MHz,	DMSO‐d6,	δ,	
ppm):	151.7	 (1C,	C=N)	 (Pyrazole),	 151.3,	145.9,	143.8,	138.4,	
137.9,	 137.1,	 132.0,	 131.6,	 131.1,	 129.5,	 129.0,	 128.7,	 127.8,	
124.6,	 123.1,	 122.9,	 119.0,	 115.5	 (32C,	 Ar‐C),	 49.5	 (1C,	 C‐N),	
38.5	 (1C,	 CH2)	 (Pyrazole).	 MS	 (ESI,	 m/z	 (%)):	 665.05	 (M+).	
Anal.	 calcd.	 for	 C35H25BrClN3O2S,	 C,	 63.02;	 H,	 3.78;	 N,	 6.30.	
Found:	C,	63.10;	H,	3.72;	N,	6.24%.	
5‐(4‐(3‐(4‐Chlorophenyl)‐1‐(m‐tolylsulfonyl)‐4,5	 ‐dihydro‐
1H‐pyrazol‐5‐yl)phenyl)‐5H‐dibenzo[b,	 f]azepine	 (40):	 Color:	
Green	solid.	Yield:	66%.	M.p:	210‐212	°C.	FT‐IR	(KBr,	ν,	cm‐1):	
3099‐2682	(Ar‐CH),	818	(C‐Cl),	1632	(C=N	pyrazole),	1368	(C‐
N).	 1H	NMR	 (400	MHz,	DMSO‐d6,	 δ	 ppm):	 6.58‐7.40	 (m,	 20H,	
Ar‐H),	6.97	(s,	2H,	Azepine‐H),	3.94	(d,	2H,	Pyrazole	alpha‐H),	
3.89	(m,	1H,	Pyrazole	beta‐H)	23.4	(s,	3H,	CH3).	13C	NMR	(100	
MHz,	 DMSO‐d6,	 δ,	 ppm):	 151.9	 (1C,	 C=N)	 (Pyrazole),	 151.6,	
143.9,	 143.6,	 137.9,	 137.6,	 132.4,	 131.4,	 131.1,	 129.4,	 129.3,	
129.0,	 128.8,	 128.2,	 127.8,	 124.6,	 123.3,	 122.9,	 119.3,	 115,	
(32C,	Ar‐C),	49.3	(1C,	C‐N),	38.5	(1C,	CH2)	(Pyrazole),	21.3	(1C,	
CH3)	(Methyl).	MS	(ESI,	m/z	(%)):	601.15	(M+).	Anal.	calcd.	for	
C36H28ClN3O2S,	 C,	 71.81;	 H,	 4.69;	 N,	 6.98.	 Found:	 C,	 71.83;	 H,	
4.72;	N,	7.02%.	
	
2.3.	Antimicrobial	studies	
	
2.3.1.	Antibacterial	studies	
	
The	 antibacterial	 activities	 of	 newly	 synthesized	
compounds	20‐40	were	 determined	 by	well	 plate	method	 in	
Mueller‐Hinton	 Agar	 [27‐29].	 The	 antibacterial	 activity	 was	
carried	 out	 against	 24	 h	 old	 cultures	 of	 bacterial	 strains	 like	
Escherichia	 coli,	 Staphylococcus	 aureus,	 and	 Pseudomonas	
aeroginosa.	 The	 test	 compounds	 were	 dissolved	 in	 dimethyl	
sulfoxide	 (DMSO)	 at	 concentration	 of	 1000	 and	 500	 μg/mL.	
Sterilized	 agar	 media	 (20	 mL)	 was	 poured	 into	 each	 pre‐
sterilized	 Petri	 dish.	 Excess	 of	 suspension	was	 decanted	 and	
plates	were	dried	by	placing	them	in	an	incubator	at	37	°C	for	
an	hour.	About	60	mL	of	24	hrs	old	culture	suspensions	were	
poured	 and	 neatly	 swabbed	 with	 the	 pre‐sterilized	 cotton	
swabs.	 Six	 millimeter	 diameter	 well	 were	 then	 punched	
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carefully	using	a	sterile	cork	borer	and	30	mL	of	test	solutions	
of	different	concentrations	were	added	into	each	labeled	well.	
The	 plates	 were	 then	 incubated	 at	 37	 °C	for	 24	 hrs.	 The	
inhibition	zone	that	appeared	after	24	hrs,	around	the	well	in	
each	 plate	 were	 measured	 as	 zone	 of	 inhibition	 in	 mm.	
Experiments	 were	 carried	 out	 in	 triplicates	 and	 standard	
deviation	was	calculated.	
	
2.3.2.	Antifungal	studies	
	
Antifungal	studies	of	newly	synthesized	compounds	20‐40	
were	 carried	 out	 against	 A.	 flavus,	 C.	keratinophilum	 and	 C.	
albicans.	Sabourands	 agar	media	was	 prepared	 by	 dissolving	
peptone	 (10	 g),	 D‐glucose	 (40	 g)	 and	 agar	 (20	 g)	 in	 distilled	
water	 (1000	mL)	 and	 adjusting	 the	 pH	 to	 5.7.	Normal	 saline	
was	used	 to	make	a	 suspension	of	spore	of	 fungal	 strains	 for	
lawning.	A	 loopful	of	particular	 fungal	 strain	was	 transferred	
to	 3	 mL	 saline	 to	 get	 a	 suspension	 of	 the	 corresponding	
species.	Agar	media	(20	mL)	was	poured	into	each	petri	dish.	
Excess	of	 suspension	was	decanted	and	plates	were	dried	by	
placing	 them	 in	 an	 incubator	 at	 37	 °C	 for	 1	 hr.	 Wells	 were	
made	on	these	seeded	agar	plates	using	sterile	cork	borer	and	
different	concentrations	of	the	test	compounds	in	DMSO	were	
added	 into	 each	 of	 the	 labeled	 wells.	 A	 control	 was	 also	
prepared	for	the	plates	in	the	same	way	using	DMSO.	The	Petri	
dishes	were	prepared	in	triplicate	and	maintained	at	25	°C	for	
72	 hrs.	 Antifungal	 activity	was	determined	by	measuring	 the	
diameter	 of	 inhibition	 zone.	 Activity	 of	 each	 compound	 was	
compared	 with	 fluconazole	 as	 standard.	 Zones	 of	 inhibition	
were	determined	for	compounds	20‐40.	
	
2.4.	Protocol	of	docking	study	
	
Synthesized	molecules	 were	 drawn	 using	 Java	molecular	
editor	 (JME)	 Molecular	 Editor	 and	 their	 3‐Dimensional	
structures	 were	 created	 and	 energy	 minimized	 using	 the	
PRODRG	 Server	 [30].	 Crystal	 structure	 of	 S.	 aureus	 tyrosyl‐
tRNA	 synthetase	 (TyrRS)	 in	 complex	 with	 its	 inhibitor	
(1jij.pdb)	 was	 downloaded.	 All	 the	 hetero‐atoms	 and	 water	
molecules	 were	 removed	 from	 the	 crystal	 structure	 and	 the	
energy	 minimized	 compounds	 were	 placed	 in	 the	 binding	
pocket,	using	PyMOL	version	1.4.1.23.	The	resultant	structure	
was	 used	 for	 the	 molecular	 docking	 studies	 using	 AutoDock	
version	4.2.		
AutoDock	4.2	 consists	of	 two	programs:	Autodock,	which	
performs	the	docking	of	the	ligand	to	a	set	of	grids	describing	
the	 target	 protein	 and	 autogrid	 pre‐calculates	 these	 grids.	
First,	 Autogrid	 was	 used	 to	 create	 the	 3‐D	 grid	 box	 of	
60*60*60	Å	size	with	a	spacing	of	0.375	Å.	The	 center	of	 the	
grid	was	choosen	as	‐12.0,	12.0	and	83.0.	Then	AutoDock	part	
of	 the	 software	 was	 used	 to	 calculate	 the	 binding	 energy	
between	 the	synthesized	compounds	and	TyrRS	enzyme.	The	
Genetic	Algorithm	with	local	search	(GA‐LS)	was	chosen	as	the	
docking	 algorithm	 with	 100	 runs,	 population	 size	 of	 150,	
maximum	number	of	27,000	generations,	2,500,000	number	of	
energy	 evaluations,	 a	 mutation	 rate	 of	 0.02	 and	 a	 crossover	
rate	of	0.8.	These	parameters	were	set	using	the	software	ADT	
(AutoDock	 Tools	 package	 version	 1.5.4).	 Results	 differing	 by	
less	 than	 2	 Å	 in	 root	 mean	 square	 deviation	 (RMSD)	 were	
clustered	 together	 and	 the	 model	 with	 the	 most	 favorable	
binding	 energy	 was	 selected	 as	 the	 resultant	 complex	
structure.		
Electrostatic	 and	 hydrophobic	 interactions	 existing	
between	 TyrRS	 and	 the	 ligands	 were	 analyzed	 by	 Ligand‐
Protein	 Contacts	 &	 Contacts	 of	 Structural	 Units	 (LPC/CSU)	
online	 server	 [31].	Hydrogen	bonds	 in	 the	 resultant	 complex	
structure	 were	 deduced	 from	 LPC/CSU	 online	 server	 results	
after	checking	for	proper	geometry	in	PyMol.	
	
	
	
2.5.	Antioxidant	studies	
	
2.5.1.	DPPH	free	radical	scavenging	assay	
	
The	evaluation	of	antioxidant	activity	of	newly	synthesized	
compounds	 20‐40	 were	 done	 by	 DPPH	 radical	 scavenging	
activity	assay	[32].	Internal	standard,	BHA	and	the	synthesized	
compounds	 of	 different	 concentrations	 were	 prepared	 in	
distilled	 ethanol.	 1	 mL	 of	 Each	 compound	 solutions	 having	
different	 concentrations	 (10,	 25,	 50,	 100,	 200	 and	 500	 µM)	
were	taken	in	different	test	tubes	and	4	mL	of	0.1	mM	ethanol	
solution	 of	 1,1‐diphenyl‐2‐picrylhydrazyl	 (DPPH)	 was	 added	
and	shaken	vigorously.	The	tubes	were	 then	 incubated	 in	 the	
dark	room	at	room	temperature	for	20	min.	A	DPPH	blank	was	
prepared	without	the	compound,	and	ethanol	was	used	for	the	
baseline	 correction.	 Changes	 (decrease)	 in	 the	 absorbance	 at	
517	nm	were	measured	using	a	UV‐visible	spectrophotometer	
and	the	remaining	DPPH	was	calculated.	The	percent	decrease	
in	 the	 absorbance	was	 recorded	 for	 each	 concentration,	 and	
percent	quenching	of	DPPH	was	calculated	on	the	basis	of	the	
observed	 decreased	 in	 absorbance	 of	 the	 radical.	 The	 radical	
scavenging	activity	was	expressed	as	the	inhibition	percentage	
and	was	calculated	using	the	formula:		 		
	
Radical	scavenging	activity	(%)	=	[(Ao‐A1)/Ao	×	100]		 (1)
	 	 	 	 	
where	Ao	is	the	absorbance	of	the	control	(without	compound)	
and	A1	is	the	absorbance	of	the	compound.		
	
2.5.2.	Inhibition	of	microsomal	lipid	peroxidation	assay	
	
Liver	 excised	 from	 adult	 male	 Wister	 rats,	 was	
homogenized	 (20	 g/100	mL	 Tris	 buffer)	 in	 0.02	mol/L,	 tris‐
buffer	 (pH	 =	 7.4).	 Microsomes	 were	 isolated	 by	 calcium	
aggregation	method.	 100	 µL	 of	 Liver	microsomal	 suspension	
(0.5	mg	protein)	was	incubated	with	1	mmol/L	each	of	FeSO4	
and	ascorbic	acid	with	or	without	compounds	in	a	total	volume	
of	 1	 mL	 in	 0.1	 mol/L	 phosphate	 buffer	 (pH	 =	 7.4).	 After	
incubation	at	37	°C	for	60	min,	the	reaction	mixture	was	boiled	
with	thiobarbutaric	acid	(TBA)	(0.67	g/100	mL	water)	for	15	
min.	 Formation	 of	 TBA	 reactive	 substances	 (TBARS)	 was	
calculated	 from	 the	absorbance	at	535	nm.	BHA	was	used	 as	
the	positive	control.	
The	inhibition	ratio	(%)	was	calculated	using	the	following	
formula:	
	
Inhibition	ratio	(%)	=	[(A0	–	A1)/A0	×	100]		 	 (2)
	 	 	 	
where,	 A0	 is	 the	 absorbance	 of	 the	 control	 and	 A1	 is	 the	
absorbance	of	the	test	sample.	
	
3.	Results	and	discussion	
	
3.1.	Chemistry	
	
5H‐Dibenz[b,f]azepine	was	 readily	 prepared	 according	 to	
the	literature	method	[33].	Coupling	reaction	of	5H‐dibenz[b,f]	
azepine	 (1)	 with	 4‐chlorobenzaldehyde	 (2)	 afforded	 4‐(5H‐
dibenz[b,f]azepine‐5‐yl)benzaldehyde	 (3).	 5H‐Dibenz[b,f]	 aze‐
pine	 based	 chalcones	 (7‐9)	 were	 synthesized	 via	 Aldol	
condensation	 by	 treating	 4‐(5H‐dibenz[b,f]azepine‐5‐yl)benz	
aldehyde	 (3)	 with	 substituted	 acetophenones	 (4‐6)	 in	 dilute	
ethanolic	 solution	of	potassium	hydroxide	at	ambient	 tempe‐
rature.	 Further,	 Claissan‐Schmidt	 condensation	 of	 respective	
chalcones	 (7‐9)	 with	 hydrazine	 hydrate	 in	 the	 presence	 of	
glacial	 acetic	 acid	 gave	 pyrazole	 substituted	 5H‐dibenz[b,f]	
azepine	derivatives	(10‐12).	Finally,	coupling	of	commercially	
available	phenylsulfonyl	 chlorides	 (13‐19)	with	10‐12	 in	 the	
presence	 of	 triethylamine	 furnished	 5H‐dibenz[b,f]azepine	
based	 pyrazole	 sulphonamides	 (20‐40)	 in	 good	 yields	
(Scheme	1).		
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Table	1.	Inhibitory	zone	(diameter)	mm	of	the	synthesized	compounds	against	tested	bacterial	strains	by	well	plate	method.	Each	value	represents	mean±SD	
(n	=	3)	*.	
*	NA:	no	activity.	
	
Table	2.	 Inhibitory	zone	(diameter)	mm	of	 the	synthesized	compounds	against	 tested	fungal	strains	by	well	plate	method.	Each	value	represents	mean±SD							
(n	=	3)	*.	
Compound	 Aspergillus	flavus	 Chrysosporium	keratinophilum Candida	albicans	
1000	(µg/mL)	 500	(µg/mL)	 1000	(µg/mL)	 500	(µg/mL)	 1000	(µg/mL)	 500	(µg/mL)	
10	 NA	 NA	 NA NA NA NA	
11	 NA	 NA	 NA NA NA NA	
12	 2±0.02	 1±0.01	 3±0.02 2±0.02 2±0.02 1±0.02
20	 4±0.01	 2±0.02	 4±0.01 3±0.01 4±0.01 2±0.01
27	 2±0.02	 10±0.01	 5±0.02	 3±0.01	 3±0.01	 2±0.01	
34	 2±0.03	 1±0.02	 5±0.01	 3±0.01	 3±0.02	 3±0.01	
21	 3±0.01	 1±0.01	 5±0.02 3±0.01 3±0.01 2±0.01
28	 6±0.02	 5±0.01	 4±0.01	 3±0.01	 5±0.01	 4±0.02	
35	 5±0.01	 3±0.02	 5±0.02	 	4±0.02	 4±0.02	 2±0.01	
22	 3±0.02	 1±0.01	 4±0.01 3±0.01 3±0.01 2±0.02
29	 3±0.01	 1±0.01	 4±0.02 3±0.02 3±0.02 2±0.01
36	 3±0.02	 	1±0.01	 5±0.02 4±0.01 3±0.01 2±0.01
23	 4±0.01	 1±0.01	 5±0.02 4±0.01 3±0.01 2±0.02
30	 4±0.01	 1±0.02	 4±0.01 3±0.02 4±0.01 2±0.01
37	 3±0.02	 1±0.02	 4±0.02 3±0.02 4±0.02 3±0.02
24	 2±0.01	 2±0.01	 4±0.01 3±0.01 4±0.01 3±0.01
31	 4±0.02	 1±0.01	 4±0.02	 3±0.02	 5±0.02	 3±0.01	
38	 16±0.01	 13±0.02	 19±0.01	 17±0.01	 25±0.01	 21±0.01	
25	 4±0.02	 3±0.02	 4±0.01	 4±0.01	 3±0.01	 3±0.02	
32	 4±0.02	 2±0.01	 5±0.02 4±0.02 3±0.02 4±0.01
39	 17±0.03	 14±0.01	 21±0.02 18±0.01 27±0.01 22±0.01
26	 3±0.01	 2±0.02	 6±0.01 5±0.01 9±0.01 8±0.02
33	 5±0.01	 4±0.01	 3±0.02 3±0.01 5±0.02 3±0.01
40	 6±0.01	 5±0.01	 5±0.01 2±0.01 5±0.01 4±0.01
Fluconazole		 13±0.01	 12±0.02	 17±0.02	 16±0.01	 22±0.02	 20±0.02	
*	NA:	no	activity.	
	
Structures	 of	 all	 the	 synthesized	 compounds	 were	
confirmed	 by	 physico‐chemical	 and	 spectroscopic	 techniques	
like	IR,	mass,	1H	and	13C	NMR.		
	
3.2.	Antimicrobial	activity	
	
The	 antimicrobial	 activity	 of	 newly	 synthesized	
compounds	20‐40	were	determined	by	well	plate	method	[27‐
29].	 The	 supremacy	 of	 the	 synthesized	 compounds	 as	
antimicrobials	 was	 assessed	 for	 their	 antibacterial	 studies	
against	different	human	pathogenic	strains	of	bacteria	namely	
Escherichia	 coli	 (ATCC25922),	 Staphylococcus	 aureus	
(ATCC25923),	 and	 Pseudomonas	 aeruginosa	 (ATCC27853).	
Antifungal	studies	were	performed	against	human	pathogenic	
fungi	 strains	 such	 as	 Aspergillus	 flavus	 (MTCC3306),	
Chrysosporium	 keratinophilum	 (MTCC3017)	 and	 Candida	
albicans	 (MTCC2827).	The	 test	 compounds	were	dissolved	 in	
dimethyl	sulphoxide	at	concentrations	of	1000	and	500	µg/mL	
and	 the	 results	 obtained	 as	 zone	 of	 inhibition	 (mm)	 are	
presented	in	Table	1	and	2.	
	
3.2.1.	Antibacterial	activity	
	
The	 antibacterial	 screening	 revealed	 that	 some	 of	 the	
tested	 compounds	 showed	 good	 inhibition	 against	 various	
tested	 microbial	 strains	 (Table	 1).	 Initially,	 pyrazole	 substi‐
tuted	 5H‐dibenz[b,f]azepine	 derivatives	 (10,11)	 showed	
negligible	 activity	whereas,	 compound	12	possessing	 electro	
negative	chlorine	group	exhibited	reasonable	activity.	Further,	
introduction	 of	 phenyl	 sulphonyl	 chlorides	 into	 the	 pyrazole	
ring	accounted	for	the	enhanced	activity.	It	is	to	be	noted	that	
the	nature	of	the	substituent	present	on	the	phenyl	ring	of	3‐
substituted	 pyrazole	 and	 phenyl	 sulphonyl	 terminus	 was	
found	to	have	the	strongest	 influence	on	the	activity	and	this	
was	 confirmed	 by	 the	 fact	 that	 the	 presence	 of	 electron	
withdrawing	 chloro	 and	 bromo	 group	 in	 compound	 39	
displayed	excellent	activity	(even	more	active	than	standard).	
Compound	 Escherichia	coli	 Staphylococcus	aureus Pseudomonas	aeroginosa	
1000	(µg/mL)	 500	(µg/mL)	 1000	(µg/mL)	 500	(µg/mL)	 1000	(µg/mL)	 500	(µg/mL)	
10	 NA	 NA	 NA NA NA NA	
11	 NA	 NA	 NA NA NA NA	
12	 4±0.02	 3±0.03	 2±0.01 1±0.01 3±0.02 	2±0.02
20	 6±0.01	 4±0.01	 3±0.02 1±0.02 4±0.02 	3±0.01
27	 5±0.01	 4±0.01	 3±0.01 1±0.01 4±0.01 3±0.01
34	 5±0.03	 4±0.02	 3±0.01	 1±0.02	 4±0.02	 3±0.02	
21	 6±0.01	 5±0.01	 3±0.02 2±0.01 6±0.01 3±0.01
28	 7±0.02	 6±0.01	 9±0.01	 7±0.01	 5±0.01	 3±0.02	
35	 9±0.01	 6±0.02	 8±0.02	 6±0.02	 6±0.02	 4±0.01	
22	 5±0.02	 4±0.01	 3±0.01 2±0.01 4±0.01 3±0.02
29	 4±0.01	 3±0.01	 3±0.02 1±0.02 3±0.03 3±0.01
36	 6±0.01	 5±0.03	 5±0.02 2±0.02 6±0.02 4±0.02
23	 4±0.01	 4±0.01	 4±0.02 2±0.02 6±0.02 4±0.02
30	 4±0.01	 3±0.02	 3±0.01 2±0.01 4±0.01 3±0.01
37	 5±0.02	 5±0.02	 4±0.02 2±0.02 4±0.02 3±0.02
24	 5±0.01	 4±0.01	 3±0.01 1±0.01 5±0.01 4±0.01
31	 5±0.02	 5±0.01	 3±0.02	 1±0.02	 7±0.02	 5±0.01	
38	 20±0.01	 16±0.01	 16±0.02	 12±0.01	 21±0.01	 17±0.01	
25	 4±0.02	 3±0.02	 3±0.01	 2±0.01	 4±0.01	 3±0.02	
32	 6±0.02	 5±0.01	 4±0.01 3±0.02 4±0.02 3±0.01
39	 22±0.02	 19±0.02	 17±0.01 11±0.01 19±0.01	 16±0.01
26	 8±0.01	 6±0.01	 5±0.02 4±0.01 8±0.02 6±0.01
33	 7±0.01	 6±0.02	 5±0.01 3±0.01 4±0.01 3±0.02
40	 6±0.01	 5±0.01	 4±0.01 3±0.01 6±0.02 4±0.01
Streptomycin		 18±0.01	 10±0.01	 15±0.02	 10±0.01	 18±0.01	 12±0.02	
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Table	3.	Comparison	of	experimentally	determined	 Inhibitory	zone	diameter	 for	S.	aureus	with	 the	molecular	docking	results	of	 compound	38	and	39	and	
streptomycin	with	S.	aureus	tyrosyl‐tRNA	synthetase.	
Compound	 	 Binding	energy	
(kcal/mol)	
Inhibition	constant	
(nM)	
Inhibitory	zone	(diameter)	mm	for	S.	aureus		
by	well	plate	method	(1000	µg/mL)		
38	 ‐11.11	 7.21 14±0.02
39	 ‐12.74	 0.46 17±0.01
Streptomycin	 ‐13.01	 0.29	 15±0.02	
	
	
Compound	38	having	functionalities	 like	nitro	and	chloro	
at	para	position	on	benzene	ring	of	sulfonamide	terminus	and	
3‐substituted	pyrazole	ring	terminus	displayed	4‐12	fold	more	
activity	 than	 compound	 12	 against	 all	 the	 tested	 bacterial	
strains	and	in	fact	the	same	compound	displayed	more	activity	
than	Streptomycin,	an	internal	standard.	From	the	studies,	the	
analogues	 holding	 electron	 donating	 hydroxyl,	 methyl	 and	
methoxy	 groups	 were	 not	 demanded	 for	 enhanced	 activity	
against	 all	 bacterial	 strains.	 This	 might	 be	 the	 reason	 for	
decreased	activity	in	compounds	21‐23,	28‐30,	35‐37	and	26,	
33,	 40	 compared	 to	 other	 analogues	 and	 standard	 drug	 as	
well.		
	
3.2.2.	Antifungal	activity	
	
The	 investigation	 of	 antifungal	 activity	 divulge	 that	
compound	39	 possessing	 electro	 negative	 bromo	 and	 chloro	
moiety	 on	 phenylsulphonyl	 ring	 and	 3‐substituted	 pyrazole	
ring	 respectively,	 emerged	 as	 the	 active	 antifungal	 agent	
against	A.	 flavus,	C.	 keratinophilum	 and	C.	albicans	 compared	
with	an	internal	standard,	fluconazole	as	well	as	against	other	
compounds	 (Table	 2).	 Whereas	 compound	 38,	 holding	 nitro	
and	chloro	group	was	the	next	effective	antifungal	species.	The	
remaining	compounds	20‐23,	27‐30,	34‐37	and	24‐25,	31‐33,	
38‐40	showed	completely	insusceptible	activity	against	all	the	
tested	 fungicidal	 strains.	 Therefore,	 modification	 of	 phenyl	
sulfonamides	 moiety	 with	 diversified	 functional	 groups	 at	
different	 positions	 can	 significantly	 improve	 the	 antifungal	
activity.	
	
3.3.	Molecular	docking	
	
To	 explain	 the	 promising	 activity	 of	 the	 synthesized	
compounds,	 molecular	 docking	 studies	 of	 synthesized	
compounds	 within	 the	 binding	 pocket	 of	 tyrosyl‐tRNA	
synthetase	(TyrRS)	was	performed.	TyrRS	is	an	enzyme	which	
ligates	 tyrosine	 to	 its	 tRNA	 molecules	 and	 thus	 plays	 an	
important	 role	 in	 protein	 production	 [34].	 Very	 recently,	 3‐
aryl‐4‐aminofuranes‐2(5H)‐ones	 were	 reported	 as	 potent	
inhibitors	 of	 TyrRS	 and	 several	 of	 them	 showed	 excellent	
antibacterial	 activity	 [35].	 Therefore,	 creating	 novel	 TyrRS	
inhibitors	 can	 act	 as	 new	 antimicrobial	 agents	 by	 arresting	
cellular	 protein	 production.	 Autodock	 4.2,	 the	 molecular	
docking	 software	 for	 studying	 the	 binding	 affinity	 of	 small	
molecule	to	enzyme	target	was	used	to	study	the	interactions	
between	 the	 active	 compounds	 and	 the	 TyrRS	 binding	 site	
[36].	Compounds	38	and	39	which	showed	the	highest	activity	
among	 the	 synthesized	 compounds	 and	 Streptomycin	 were	
docked	 into	 the	 binding	 site	 of	 TyrRS	 based	 on	 the	 crystal	
structure	of	TyrRS	complex	structure	(1jij.pdb)	[37].	
The	docking	results	showed	that	compound	38	and	39	and	
Streptomycin	are	held	to	the	active	site	by	several	electrostatic	
and	hydrophobic	 interactions.	The	computational	determined	
binding	energy	and	inhibition	constant	values	of	compound	38	
and	39	matches	closely	with	that	of	Streptomycin	(Table	3).	In	
the	 docking	 model	 generated	 for	 compound	 39	 (the	 most	
active	 compound),	 the	 seven‐membered	 ring	 5H‐dibenz[b,f]	
azepine	nucleus	moiety	 and	 the	pharmacologically	 important	
sulphonamide	linked	pyrazole	moiety	are	located	towards	the	
entrance	 of	 the	 cavity	 (Figure	 3	 and	 4).	 This	 causes	 the	
substituted	 phenyl	 ring	 attached	 to	 the	 pyrazole	 moiety	 to	
interact	 with	 active	 site	 residues	 inside	 the	 cavity.	 The	 5H‐
dibenz[b,f]azepine	 nucleus	 moiety	 forms	 hydrophobic	
interaction	 with	 Ala43,	 His47,	 His50	 and	 Trp241	 whereas	
sulphonamide	 linked	 pyrazole	 moiety	 forms	 hydrophobic	
interaction	 with	 Ala39,	 His50,	 Pro53.	 Due	 to	 the	 strong	
hydrophobic	interaction	of	the	above	moieties	at	the	entrance	
of	 the	 cavity,	 we	 predict	 that	 our	 compounds	 act	 as	 a	
competitive	 inhibitor	 by	 preventing	 substrate	 binding,	 thus	
leading	 to	 higher	 potency.	 The	 bromine	 atom	 in	 the	 phenyl	
sulphonamide	moiety	as	acceptor	forms	H‐bond	with	H	(‐CH2)	
of	 Pro53	 at	 3.3	 Å	 and	H	 (‐CH2)	 of	 Gly193	 at	 3.6	 Å.	 Carbonyl	
oxygen	 of	 Gln196	 forms	 a	 strong	 H‐bond	 with	 ‐NH	 of	 the	
pyrazole	 ring	 at	 2.7	 Å	 and	 ‐NH2	 hydrogen	 of	 Gln196	 forms	 a	
hydrogen	 bond	 with	 N	 of	 pyrazole	 moiety	 at	 3.7	 Å.	 Oxygen	
atom	(‐SO2)	of	the	sulphonamide	moiety	as	acceptor	forms	H‐
bond	 with	 H	 (–SH)	 of	 Cys37	 at	 2.7	 Å.	 Chlorine	 atom	 of	 the	
substituted	phenyl	ring	attached	to	the	pyrazole	moiety	forms	
H‐bonding	interactions	with	H	(meta‐CH)	of	Tyr36	at	3.0	Å,	H	
(‐CH2)	 of	 Gln174	 at	 2.9	 Å	 and	 H	 (‐CH2)	 of	 Asp177	 at	 3.1	 Å	
(Figure	5).		
	
		
Figure 3.	High	ranked	compound	38 docked	in	the	binding	site	of	S.	aureus
tyrosyl‐tRNA	synthetase.	Protein	 is	 represented	as	 cartoons,	 residues	with	
less	 than	 6	 Å	 from	 ligand	 as	 surface	 and	 ligand	 as	 sticks.	 This	 figure	was	
made	using	PyMol.	
	
		
Figure 4.	High	ranked	compound	39	docked	in	the	binding	site	of	S.	aureus
tyrosyl‐tRNA	synthetase.	Protein	 is	 represented	as	 cartoons,	 residues	with	
less	 than	 6	 Å	 from	 ligand	 as	 surface	 and	 ligand	 as	 sticks.	 This	 figure	was	
made	using	PyMol.	
	
Thus,	 compound	39	being	 the	most	active	compound	can	
be	 attributed	 to	 the	 several	 H‐bonds	 and	 hydrophobic	
402	 Kumar	et	al.	/	European	Journal	of	Chemistry	6	(4)	(2015)	394‐403	
	
interactions	 it	 forms	 with	 TyrRS	 (Figure	 6).	 The	 above	
discussed	docking	 results	 unveiled	 that	 the	 seven‐membered	
ring	 5H‐dibenz[b,f]azepine	 nucleus	 moiety	 and	 the	 electron	
withdrawing	 group	 in	 the	 sulphonamide	 linked	 pyrazole	
moiety	 had	 an	 significant	 effect	 on	 the	 interactions	 of	 the	
TyrRS‐39	complex	and	thus	were	crucial	to	the	TyrRS	binding.	
Bulkiness	 of	 ‐NO2	 group	 in	 compound	 38	 causes	 the	 5H‐
dibenz[b,f]azepine	nucleus	moiety	 to	be	 located	at	a	different	
part	of	the	active	site	compared	to	compound	39	due	to	steric	
hindrance	(Figure	3	and	4),	causing	slight	decrease	in	binding	
energy,	which	is	supported	by	the	decrease	in	inhibitory	zone	
diameter	(Table	3).	
	
		
Figure	5.	Superposition	of	compound	38	and	39	docked	in	the	binding	site	
of	 aaTYrS.	 Compound	 38	 and	 39	 are	 represented	 as	 red	 and	 blue	
respectively.	This	figure	was	made	using	PyMol.	
	
		
Figure	 6.	 Hydrogen	 bonding	 interaction	 of	 compound	 39	 docked	 in	 the	
binding	 site	 of	 S.	 aureus	 tyrosyl‐tRNA	 synthetase.	 Hydrogen	 bonding	
interactions	are	shown	in	dash.	Hydrogen‐bonded	residues	are	labeled	and	
shown	as	sticks.	This	figure	was	made	using	PyMol.	
	
3.4.	Antioxidant	activity	
	
3.4.1.	DPPH	free	radical	scavenging	activity	
	
In	 order	 to	 probe	 the	 antioxidant	 potential	 of	 the	 newly	
synthesized	 compounds,	 in	 vitro	 models	 were	 adopted	 for	
evaluation.	 Antioxidant	 activity	 for	 the	 newly	 synthesized	
compounds	 were	 done	 by	 using	 two	 assays:	 2,2‐diphenyl‐1‐
picryl‐hydrazyl	 (DPPH)	 radical	 scavenging	 activity	 [32]	 and	
inhibition	 of	 microsomal	 lipid	 peroxidation	 (LPO)	 [38].	 The	
antioxidant	 properties	 were	 expressed	 as	 50%	 inhibitory	
concentration	 (IC50)	 (Table	 4).	 The	 DPPH	 radical	 scavenging	
evaluation	 is	 a	 standard	 assay	 in	 antioxidant	 activity	 studies	
and	 offers	 a	 rapid	 technique	 for	 screening	 the	 radical	
scavenging	activity	(RSA)	of	specific	compounds.	Interaction	of	
the	 synthesized	compounds	 with	 stable	 DPPH	 free	 radical	
indicates	 their	 free	 radical	 scavenging	 ability.	 5H‐
Dibenz[b,f]azepine	based	pyrazole	scaffold	compound	10	and	
12	 displayed	 less	 activity	 but	 compound	 11	 exhibited	
substantial	 activity,	 this	 could	 be	 due	 to	 the	 presence	 of	
electron	donating	hydroxyl	group	at	3‐substituted	phenyl	ring	
and	also	the	presence	of	N‐H	functional	group	in	the	pyrazole	
moiety	 (Table	 4)	 [39].	 Eventually,	 coupling	 of	 phenyl	
sulphonyl	chlorides	to	compound	10‐12	enhanced	the	activity	
significantly.	 Majority	 of	 the	 tested	 compounds	 in	 the	 series	
20‐40	 showed	 moderate	 to	 high	 activity.	 Interestingly,	
compounds	 28	 and	 29	 possessing	 two‐hydroxyl	 groups	 and	
compound	30	holding	methoxy	and	hydroxyl	group	on	the	N‐
substituted	phenyl	sulphonamide	ring	of	the	pyrazole	skeleton	
as	well	 as	 in	 3‐substituted	 phenyl	 ring	were	 standout	 as	 the	
most	 efficacious	 scaffolds.	 Whereas,	 compound	 28	 and	 29	
possessing	 one‐hydroxyl	 group	 at	 different	 position	 on	 the	
phenyl	ring	showed	13‐14	fold	more	activity	than	the	scaffold	
(11).	 The	 electron	 or	 hydrogen	 donating	 ability	 of	 nitrogen	
based	 DPPH	 radical,	 which	 eventually	 become	 stable	
diamagnetic	material	plays	a	significant	role	for	the	enhanced	
antioxidant	 activity	 of	 these	 compounds	 among	 the	
synthesized	 compounds	 and	 internal	 standard	 as	 well.	 The	
introduction	 of	 phenyl	 sulphonyl	 chlorides	 holding	 electron	
withdrawing	 groups	 (NO2	 and	 Br)	 to	 compound	 10‐12	was	
inadequate	for	the	enhanced	activity	in	compound	24,	25;	31,	
32;	 38,	 39	 whereas,	 the	 compounds	 22,	 23,	 36	 and	 37	
containing	electron	releasing	hydroxyl	and	methoxy	groups	at	
different	 position	 of	 sulphonamide	 phenyl	 ring	 exhibited	 2‐4	
fold	more	 RSA	 activity	 than	 the	 scaffolds	 (10‐12)	 (Table	 4).	
Since,	compound	20,	27	and	34	does	not	have	any	substituent	
on	 the	 sulphonamide	 phenyl	 ring	 as	well	 as	 in	 3‐substituted	
phenyl	 ring,	 it	 was	 the	 least	 active	 scaffold	 among	 the	
compounds.	
	
Table	4.	50%	Inhibition	of	DPPH	radical	and	microsomal	LPO	inhibition	by	
prepared	compounds.	Each	value	represents	mean±SD	(n	=	3).	
Compound DPPH	activity	
IC50	(μM/mL)	a	
LPO	inhibition	
IC50	(μM/mL)	b	
10 158±0.43 175±0.75	
11 125±0.55 143±0.22	
12 188±0.61 203±0.63	
20 80±0.33 92±0.42	
27	 28±0.10	 33±0.11	
34	 70±0.53	 81±0.67	
21	 20±0.44	 34±0.60	
28 08±0.60 12±0.01	
35	 81±0.31	 97±0.78	
22 55±0.77 63±0.82	
29 09±0.11 13±0.10	
36 83±0.23 90±0.95	
23 79±0.23 88±0.94	
30 10±0.33 16±0.45	
37 40±0.12 50±0.12	
24	 38±0.38	 67±0.77	
31 33±0.14 45±0.70	
38	 160±0.66	 180±0.65	
25	 55±0.72	 78±0.44	
32 47±0.33 62±0.36	
39 73±0.52 85±0.07	
26 124±0.11 116±0.47	
33 132±0.70 150±0.66	
40 95±0.42 106±0.42	
BHA	 11±0.01	 16±0.32	
a	IC50	=	The	concentration	exhibiting	50%	inhibition	of	DPPH	radical.	
b	IC50	=	The	concentration	exhibiting	50%	inhibition	of	LPO	oxidation.	
	
3.4.2.	Inhibition	of	microsomal	lipid	peroxidation	activity	
	
Inhibition	 of	 lipid	 peroxidation	 property	 of	 the	 newly	
synthesized	 compounds	were	performed	by	 the	 formation	 of	
thiobarbutaric	 acid	 reactive	 species	 (TBARS)	 using	 liver	
excised	from	adult	male	Wister	rats.	The	free	radicals	tend	to	
stabilize	 by	 a	 molecular	 rearrangement	 to	 produce	 a	 conju‐
gated	diene,	which	then	readily	reacts	with	oxygen	molecule	to	
give	a	peroxy	 radical.	 In	 this	assay,	 all	 the	newly	synthesized	
compounds	20‐40	 inhibited	 the	 ferric	 chloride	 induced	 lipid	
peroxidation	 by	 varying	 degree	 compared	 to	 the	 standard	
antioxidant	BHA	(Table	4).	Compounds	28‐30	which	contains	
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hydroxyl	 (‐OH)	 and	 methoxy	 (‐OMe)	 groups	 on	 the	
sulphonamide	 phenyl	 ring	 and	 3‐substituted	 phenyl	 ring	 of	
pyrazole	 moiety	 ideally	 suits	 for	 the	 enhanced	 activity.	 In	
general,	 the	 presence	 of	 electron‐donating	 groups	 on	 the	
phenyl	ring	favors	the	activity.	This	might	be	the	reason	for	the	
12‐17	 fold	 enhancement	 of	 activity	 compared	 to	 compound	
10‐12.	 Whereas,	 compound	 24,	 25;	 31,	 32;	 38,	 39	 holding	
electron	withdrawing	 groups	 (NO2,	 Cl	 and	Br)	 on	 the	 phenyl	
rings	was	not	demanded	for	improved	antioxidant	efficacy.	
	
5.	Conclusions	
	
In	 this	study,	we	have	achieved	a	convenient	protocol	 for	
the	 synthesis	 of	 5H‐dibenz[b,f]azepine	 based	 pyrazole	
sulphonamides	 (20‐40)	 by	 simple	 and	 efficient	 reaction	
pathway	 and	 there	 in	 vitro	 antioxidant	 and	 antimicrobial	
activities	 were	 evaluated.	 Among	 the	 analogues,	 compounds	
38	and	39	possessing	electron	withdrawing	groups	like	Cl,	Br	
and	 NO2	 on	 the	 phenyl	 rings	 showed	 excellent	 antimicrobial	
activity	against	all	tested	microbial	strains	and	displayed	even	
more	 activity	 than	 their	 corresponding	 internal	 standard.	
Molecular	 docking	 study	 showed	 good	 binding	 of	 these	
compounds	 to	 the	 tyrosyl‐tRNA	 synthetase	 active	 site.	 It	 is	
noteworthy	 that	 compounds	 28‐30	 possessed	 potent	
antioxidant	 activity	 than	 the	 standard	 because	 of	 having	
highest	phenolic	content.	Overall,	the	biological	tests	revealed	
that	 the	 introduction	 of	 phenyl	 sulfonyl	 chlorides	 into	 5H‐
dibenz[b,f]azepine	 based	 pyrazole	 core	 moiety	 leads	 the	
exceptional	platform	for	probing	the	bioactivity.		
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